Doximity (DOCS), ranked fifth on the IBD 50, surprised Wall Street with its fiscal third-quarter results, crushing expectations and raising its full-year outlook. The company’s stock surged 23.4% to $71.90, breaking out of a consolidation phase.
For the quarter, Doximity reported adjusted earnings per share (EPS) of 45 cents, exceeding analyst expectations by 34 cents and beating Wall Street estimates. Sales jumped 25%, reaching $168.6 million, with over 610,000 unique providers using its clinical workflow tools.
The company’s growth is driven by its AI tools, which saw a 60% increase in the third quarter. Doximity’s newsfeed also surpassed one million unique providers.
In a statement, CEO Jeff Tangney expressed pride in delivering another quarter of record engagement. The company has now raised its full-year guidance for adjusted EPS and sales, with expectations ranging from $306.6 to $307.6 million, surpassing forecasts by over $20 million.
Doximity’s stock holds strong ratings, including a perfect IBD Digital Composite rating and an EPS rating of 99, indicating it ranks among the top 1% of stocks in terms of fundamental and technical measures. Its Relative Strength Rating stands at 97, reflecting its strong 12-month performance.
Source: https://www.investors.com/news/technology/doximity-stock-doximity-earnings-q3-2025